previous findings of a high correlation between microvessel counts and both total metachromatic MC and tryptase-reactive MC in Bcell non-Hodgkin's lymphoma, multiple myeloma and myelodysplastic syndromes. [5] [6] [7] [8] In conclusion, our data indicate that the tryptase contained in the secretory granules of MC may be an effector of MCinduced angiogenesis in B-cell CLL. They also suggest that tryptase antagonization could be employed in the treatment of B-cell CLL.
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TO THE EDITOR
Chronic myeloid leukaemia (CML) is a myeloproliferative disease of stem cell origin, characterised by the presence of the Philadelphia (Ph) chromosome and a BCR-ABL fusion gene that is believed to be causal to the disease. CML cells display changes in many intracellular signalling pathways normally activated by growth factor receptors, suggesting a variety of mechanisms by which these cells might acquire reduced dependence on normal growth factor stimulation or decreased responsiveness to inhibitory factors. 1 This is now known to involve the autocrine production of growth factors, specifically IL-3 and G-CSF, by the CD34 + leukaemic cells in chronic phase (CP) CML patients.
2,3 Such a mechanism was initially suggested by studies of the effects of enforced expression of p210 BCR-ABL in immortalised growth factor-dependent cell lines. 4, 5 Autocrine production of IL-3 and GM-CSF was later confirmed in p210 BCR-ABL -transduced murine bone marrow cells both before and after their transplantation into irradiated mice. 6, 7 It was therefore of interest to determine whether autocrine growth factor production by primary CML cells in patients also increases their levels in the periphery, and if so, how these change with disease progression. We now describe the interesting results of an analysis of serum samples from a large series of CML patients that show stage-specific changes in circulating levels of G-CSF but not IL-3.
A total of 177 peripheral blood samples (all collected with informed consent) were analysed. Of these, 135 were from CML patients, 38 were from normal controls, and four were from patients with elevated white blood cell (WBC) counts after surgery unrelated to any malignancy. Of the CML patients, 63 were studied in CP including 26 at diagnosis (CP-Dx), 37 on treatment with hydroxyurea or busulphan (CP-Rx), and 22 before and after 400 mg/day oral imatinib. 56 were in accelerated phase/blast crisis (AP/BC) including four who had been initially studied in CP and nine who were studied before and after 600 mg/day oral imatinib, and 16 who had received an allogeneic transplant (postallo BMT) and were in complete molecular remission. All serum samples were frozen (at À201C) until assessment of cytokine content by sensitive ELISA.
The results of both the IL-3 and G-CSF serum measurements are shown in Figure 1 . Serum IL-3 levels averaged o2 pg/ml in normal controls and similar levels were seen in the sera of 14 'normal' postallo BMT CML patients in molecular remission. Notably, the serum IL-3 levels in CML patients with active disease at any stage were not significantly different. These data indicate that the amounts of IL-3 produced by CD34 + CML cells in vivo is insufficient to alter the levels detectable in the circulation, even in patients with advanced disease.
Normal G-CSF levels were 21.271.6 pg/ml (n ¼ 23) and, in sera from four non-malignant controls with elevated WBCs postsurgery, an expected elevation to 43 times the normal value (787 3 pg/ml, Po0.001) was evident. Normal circulating levels were again seen in the postallo BMT group of 'cured' CML patients. However, in CP-Dx patients, the mean G-CSF level was significantly reduced (420-fold, Po0.001). Moreover, the CP-Rx patients given treatments that lowered their WBC count without a cytogenetic response, had a significantly higher mean serum G-CSF level than the CP-Dx group patients that significantly lowered their WBC counts increased the serum G-CSF level, albeit not significantly. Nine of these patients were followed for another 12 weeks on imatinib therapy at which stage the mean serum G-CSF level had risen even further to 25 pg/ ml, although this additional increase also did not reach statistical significance.
When sera from patients with more advanced AP disease were examined, the average G-CSF level was significantly higher than in CP-Dx patients and was not significantly different from normal controls or CP-Rx patients (Figure 1) . Interestingly, in a group of nine AP patients, assessed before and after a 4-week course of imatinib that normalized their WBC count, the mean G-CSF level in the serum also increased (Figure 3b) .
Primitive CML cells produce and respond in vitro to two autocrine growth factors, IL-3 and G-CSF. 2, 3 Here, we show in a large series of patients with CML that the IL-3 produced is insufficient to allow its accumulation in the serum above normal levels, in spite of the likely presence of 410 10 IL-3-producing CD34 + CML cells in a patient with a WBC count of 10 11 /l, with as many as a half of these cells Serum IL-3 and G-CSF levels in CML patients at different stages of disease. Serum IL-3 (&) averaged 1.470.7 pg/ml in normal controls (n ¼ 24) and 1.971.6 pg/ml in the sera of 14 'normal' postallo BMT (CML) patients in molecular remission. The serum IL-3 levels in CML patients were not significantly elevated at any stage of the disease with respect to normal controls (CP-Dx, 2.471.8 pg/ml, n ¼ 12; CPRx, 1.171.0 pg/ml, n ¼ 20; and AP, 2.970.9 pg/ml, n ¼ 24, P40.2). The average value for serum G-CSF (') from analysis of normal control sera was 21.271.6 pg/ml (n ¼ 23) and was not significantly different in the postallo BMT group at 17.772.2 pg/ml (n ¼ 13, P ¼ 0.2). In the CP-Dx patients, the mean G-CSF level was significantly reduced (0.970.4 pg/ml, n ¼ 23, and undetectable, i.e.o0.1 pg/ml in 61% of these cases, Po0.001). CP-Rx patients had significantly reduced levels of serum G-CSF (9.171.2 pg/ml, n ¼ 26, Po0.001) in comparison with normal controls. In the AP group, the average G-CSF level (14.873.1 pg/mL, n ¼ 49) was significantly higher than in CP-Dx (P ¼ 0.003) but was not significantly different from normal controls (P ¼ 0.17). WBC (×10 6 / mL) G-CSF (pg / mL) a b Figure 3 Comparison of the serum G-CSF levels and the WBC count in CML patients in response to treatment with imatinib. Relation between WBC (light bars) and serum G-CSF levels (dark bars) in CP (n ¼ 22) and AP (n ¼ 9) CML patients before and after 4 weeks of treatment with imatinib at 400 and 600 mg daily, respectively. Error bars represent standard error of the mean (s.e.m). A 4-week course of imatinib therapy that significantly lowered the WBC count in CP patients (from 22.876.3 to 4.970.5 Â 10 9 /l, n ¼ 22, P ¼ 0.007) also increased the serum G-CSF level (from 10.872 to 17.173.7 pg/ml, n ¼ 22, P ¼ 0.14). In nine AP patients, a 4-week course of imatinib that normalized their WBC count (from 34.6712.4 to 3.870.8 Â 10 being in the circulation. This suggests that normal mechanisms for the rapid removal or degradation of endogenously produced IL-3 are not saturated by the levels attained in CML patients. The differences seen between patients with disease and the reported mouse transduction models may reflect differences in the amount of IL-3 produced per cell in the two situations as suggested by the observation of much higher levels of intracellular p210 BCR-ABL in transduced cells. 8 However, regardless of the mechanism, the present studies demonstrate that monitoring IL-3 serum levels in CML patients has no prognostic value.
We have confirmed that serum G-CSF levels are normally severalfold higher than those reported for IL-3 and can be physiologically elevated. It was therefore even more surprising to find that the increased WBC count (and hence inferred increased numbers of CD34 + CML cells) characteristic of this disease is associated with a proportionate decrease in the serum levels of this growth factor. In summary, in CML patients, a presumed elevation in endogenously produced IL-3 by the neoplastic CD34 + cells does not increase the level of IL-3 in the peripheral blood including patients with advanced disease. This suggests that the functional role of the autocrine IL-3 produced by primitive CML cells may be locally restricted. In the case of G-CSF, serum G-CSF levels appear to be actively suppressed in CP patients by a mechanism that may be mediated by the more mature WBCs -possibly through the release of a soluble G-CSF-R. Importantly, an increase in serum G-CSF in imatinib-naive patients may presage transformation to blast crisis. 
Mixed lineage leukemia (MLL) gene disruptions, especially translocations t(4;11)(q21; q 23) and t(11;19)(q23; p13), account for 60-70% of the rearrangements found in infant acute leukemia (AL). 1 In such translocation events, the N-terminal region of MLL is maintained, while the MLL and fusion partner C-terminals are exchanged. The MLL gene located at 11q23 encodes for a predicted 431 kDa protein that is proteolytically processed into two fragments (300 and 180 kDa) accordingly. 2 Fusion proteins that lack the cleavage site are thought to play an important role in the leukemogenesis process. The MLL gene has been extensively characterized and several important functional domains have been isolated including the central PHD finger and C-terminal SET domain. (reviewed in Ayton and Cleary 3 ) N-terminal domains include the AT hooks and a region with homology to DNA methyltransferase. Functional studies have tried to establish the role of these domains in the malignant process.
3,4 Three short motifs, known as AT hooks are thought to mediate the targeting of MLL to its nuclear site 4 and permit specific binding to the minor groove of ATrich DNA. These motifs, the theme of our study, are thought to be critical for leukemogenesis 4 and may indirectly stabilize protein-DNA interactions by inducing conformational changes, such as DNA bending, which may in turn effect the binding of specific transacting factors or facilitate the protein-protein interactions that control gene expression. Taken together, this information suggested to us a possible role for mutations in the AT-hook region being a basis for cell transformation in those patients without detectable MLL involvement. In order to fully characterize the possible molecular changes in the MLL AT-hook motifs, we have studied the AT-hook DNA sequence and its variability in cases of infant AL.
DNA samples from 23 infant AL were analyzed in this study and comprised 10 cases of ALL, eight of AML and five biphenotypic leukemias. Patients were separated into two groups, the first composed of 18 cases with MLL translocations, the second five cases without MLL disruption according to molecular analysis independent of leukemia subtype. The MLL translocations were
